Novo Nordisk

Novo Nordisk Resubmits Awiqli® and Submits Mim8 BLA to FDA for Diabetes and Hemophilia A

On September 29, 2025, Novo Nordisk submitted Biologics License Applications (BLA) for Awiqli® (icodec) and Mim8 to the U.S. FDA. Awiqli® offers once-weekly basal insulin for adults with type 2 diabetes, while Mim8 provides a highly effective non-factor prophylactic treatment for hemophilia A.

Oral Semaglutide

Novo Nordisk Secures First Oral GLP-1 Cardiovascular Approval in EU

Novo Nordisk’s Rybelsus® is now the first oral GLP-1 RA approved in Europe with cardiovascular benefit, following positive SOUL trial results. This milestone reshapes the GLP-1 landscape, combining oral convenience with outcomes data, and may accelerate adoption in China’s type 2 diabetes market.

semaglutide biosimilars

Semaglutide Mania in China: Inside the Biosimilar Gold Rush

China’s semaglutide market is heading toward $61B by 2032, unleashing a biosimilar frenzy. Over 25 drugmakers have filed 90+ applications, eight are nearing approval, and a pending patent ruling could trigger price wars that reshape diabetes and obesity care.